Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphatic Disease clinical trials
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Lymphatic Disease: 3 US clinical trials tracked, none currently recruiting.
Lymphatic Disease is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. The most active sponsor is Newport Pharmaceuticals International, running 2 of these trials.
Enrollment posture brief
Registry condition lymphatic-disease
OPEN 0 | RECR 0% | LATE 0 | EARLY 0 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Lymphatic Disease has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphatic Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphatic Disease is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
Glaxo Wellcome
NCT00002048
A Study of Isoprinosine in Patients With Lymph Node Disease
Newport Pharmaceuticals International
NCT00002297
A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy
Newport Pharmaceuticals International
NCT00002061
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on Lymphatic Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphatic Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphatic Disease page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Lymphatic Disease trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Newport Pharmaceuticals International sponsors the most Lymphatic Disease trials on record, review their full trial history before evaluating a specific study. See Newport Pharmaceuticals International's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphatic Disease condition card totals 3 registered trials; most-linked intervention Inosine pranobex; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.